EUCTR2006-005747-29-IT进行中（未招募）不适用
Evaluation of the relationship between HDL quantity and HDL functionality in patients treated with HDL-C raising drugs - PROTOCOL BP20843B HDL FUNCTIONALITY
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- ROCHE
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male and post-menopausal female, lipid treatment naïve or previously treated patients2. Age 18 - 75 years (inclusive).3. Low < 40 mg/dL and normal HDL-C levels (between 40 and 59 mg/dL).4. LDL-C levels: >130 mg/dL, but < 190 mg/dL. 5. Triglyceride levels: >150 mg/dL, but <400 mg/dL. 6.Written informed consent (approved by the Independent Ethics Committee [IEC])obtained prior to any study specific screening procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Subjects with secondary causes for Dyslipidemia (i.e. diabetes mellitus, hypothyroidism, obstructive liver disease, chronic renal failure).2. Body Mass Index (BMI) ³ 30 kg/m2.3. Patients requiring drugs that increase LDL-C and decrease HDL-C [progestins, anabolic steroids, and corticosteroids].4. Patients who drink alcohol excessively, defined as more than 21 units/week for males and more than 14 units/week for females. An alcohol unit is defined as 10 mL of absolute alcohol, 300 mL beer, 25 mL of a single spirit, or 100 mL of wine.5. History of or current alcohol or drug abuse.6. Use of an investigational drug in the 3 months prior to the screening visit. 7. Any clinically significant medical condition that could interfere with the conduct of the study.8. Systolic blood pressure ³ 160 mmHg and/or diastolic blood pressure ³ 100 mmHg at the screening visit.9. History of obstructive biliary disorders, pancreatitis, collagen diseases, or auto-immune diseases.10. History of malignancy during the 3 years prior to the screening visit.11. Known or suspected diagnosis of hepatitis or human immunodeficiency virus (HIV) infection.12. Known thyroid dysfunction.13. Any past history of cerebro-vascular accident or coronary events, including unstable angina, myocardial infarction, angioplasty, or coronary artery bypass graft.14. Females who are pregnant or breast feeding and females of child bearing potential. 15. Clinically significant hepatic, renal or cerebral disease.16. Hepatic transaminases or creatine phosphokinase >2 times the upper limit of normal (ULN) at the screening visit.17. Unable or unwilling to comply with the protocol requirements, or deemed by the investigator to be unfit for the study.18. Subjects contraindicated for PPAR-alfa agonist; or slow release niacin treatment according to approved label19. Lipid modifying drugs20. Any concomitant therapy known to alter any of the parameters to assess (i.e., aspirin, except when aspirin is indicated for the prevention of severe flushes induced by Niaspan) 21. Hypersensitivity to PPAR- alfa agonist; or slow release niacin
研究者
相似试验
进行中（未招募）
1 期
Evaluation of the relationship between HDL quantity and HDL functionality in patients treated with HDL-C raising drugs - HDL functionalityEUCTR2006-005747-29-FRF. HOFFMANN-LA ROCHE LTD80
已完成
不适用
Analysis of the effects of HDL function in coronary artery disease and search of a new target for the treatment of arteriosclerosisCoronary Artery DiseaseJPRN-UMIN000009281Kyoto University Graduate School of Medicine, Department of Cardiovascular Medicine200
已完成
不适用
Characterization of functionality of HDL in patients with familial hypercholesterolemia100146991001331710003216NL-OMON29851Erasmus MC, Universitair Medisch Centrum Rotterdam36
招募中
不适用
A study of the relationship between the HLA-DR beta 1 genotype and therapeutic response of abatacept (ABT) in patients with rheumatoid arthritis (RA)Rheumatoid arthritisJPRN-UMIN000020046Matsuyama Red Cross Hospital130
招募中
2 期
Relationship between length of hospital stay and outcome, quality of life and complicationsIRCT20200217046523N13Esfahan University of Medical Sciences60